Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma
Sponsor: Bristol-Myers Squibb
Listed as NCT00005792, this PHASE1 trial focuses on Multiple Myeloma and Plasma Cell Neoplasm and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 12 times since 1998, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jul 2019 — Dec 2019 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Feb 2019 — Jul 2019 [monthly]
Completed PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- H. Lee Moffitt Cancer Center and Research Institute
- SmithKline Beecham
For direct contact, visit the study record on ClinicalTrials.gov .